CDK4 and neoplasm: A phase 1/2 study looking at dual CDK2 and CDK4/6 inhibitor after progression on CDK4/6 inhibitors in multiple tumor types is also ongoing and addresses a key resistance mechanism to these agents [56] (Table 1).